ProText Mobility, Inc. (OTC:TXTM)
| Market Cap | 13.43M+165.4% |
| Revenue (ttm) | 0 |
| Net Income | 500.51K+1341.6% |
| EPS | 0.00 |
| Shares Out | 1.95B |
| PE Ratio | 69.00 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,035,484 |
| Open | 0.01 |
| Previous Close | 0.01 |
| Day's Range | 0.01 - 0.01 |
| 52-Week Range | 0.00 - 0.01 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About TXTM
ProText Mobility, Inc., a biotech company, engages in the development of pharmaceutical botanical medicines. Its medicines are formulated with highly-bioavailable plant extracts. The company is based in Fort Lauderdale, Florida.
$TXTM stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in TXTM holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TXTM's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TXTM Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New TXTM patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TXTM from public contracts
Source: USAspending.gov
TXTM Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TXTM’s recent data — informational, not investment advice